MIV Therapeutics Presents Transcript of Latest Investor Conference Call Recapping Company's Milestone Achievements and Strategic Plans for 2007 and Beyond.

President Highlights Stent Industry, Company's Next Generation Products and Mission to Capitalize on Estimated $6 Billion Market

ATLANTA -- MIV Therapeutics Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, invites investors to view a transcript of the Company's recent investor conference call, during which President Dr. Mark Landy recapped the Company's major achievements for the first half of 2007 and detailed the Company's strategic initiatives for the year ahead and beyond.

"The first half of 2007 has been a transforming period for us," said Dr. Landy. "We have turned MIVT from a coating company into a full-fledged stent company with a very unique and valuable technology that can be applied to stents and other medical devices."

MIVT is developing a next-generation cardiovascular stent technology being designed to provide substantial health and safety benefits and outcomes over previous generations of drug-eluting stents. MIVT has developed a new line of both ultra-thin and drug-carrying cardiovascular stent coatings based on its proprietary hydroxyapatite (HAp) technology.

During the conference call, Dr. Landy provided investors with a brief overview of the current state of the estimated $6 billion market for cardiac stents. Dr. Landy commented, many physicians he comes in contact with are very excited with the prospect for a new, safer, drug-eluting stent, so they once again can offer patients a product that significantly reduces the chance of having to have a repeat procedure. "This is exactly where MIVT has the opportunity to revolutionize the drug-eluting stent industry and make a difference," said Dr. Landy.

Dr. Landy detailed some of the significant advantages of the Company's hydroxyapatite-coated stent technology. One of the core differences with MIVT's stent, is it contains less than 50% of the drug currently found on commercial products today. "Animal trials conducted at one of the world's leading stent research centers showed MIVT's stent achieved as good as, and in some cases better results, with our advanced technology than a leading commercially available product," said Dr. Landy. "MIVT has the opportunity to bring to market a drug-eluting stent that is as safe as a bare metal stent," said Dr. Landy.

Recently, MIVT announced the first ever human implantation of a hydroxyapatite coated drug eluting stent and the launch of the MIVT Pilot Trial. The MIVT Pilot Trial will evaluate the safety and efficacy of MIVT's polymer-free nanoscale microporous hydroxyapatite drug-eluting stent for the treatment of single de novo lesions in native coronary arteries.

"In February, we closed the Biosync Scientific transaction," continued Dr. Landy. "In May, we established a presence in Europe by partnering with QUILT Solutions and on the 31st of May, we announced the first ever Human implantation of a Hydroxyapatite coated polymer-free drug-eluting stent. "And most recently, we significantly increased our visibility in the institutional investment community with our recently announced private placement of units for $12.55 million.

"For the remainder of 2007, we will continue to work diligently to increase shareholder value, move our products closer to commercialization and grow our revenues from currently approved products. In conclusion, our goals for this period include closing the Vascore transaction, beginning of animal trials for a second generation polymer-free drug-eluting stent, finalization of planning for a second human clinical trial and the release of interim data from the MIVT pilot human clinical trial," concluded Dr. Landy.

To read the full text or listen to an audio cast of the recent conference call, please visit http://www.trilogy-capital.com/tcp/html/mivt.htm.

About MIV Therapeutics Inc.

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage. MIVT's intellectual property portfolio includes patents held by the University of British Columbia (UBC). MIVT has worldwide exclusive rights to the technologies licensed from UBC. Key patent applications filed simultaneously in various countries around the world, further protect the commercial exclusivity of MIVT's own inventions in the global marketplace.

For more information, please visit www.mivtherapeutics.com or http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "proposed," "expected," "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties including, without limitation, the potential for the unsuccessful closing by the Company of its Vascore acquisition, together with the raising of funding sufficient to continue with its operations and those contemplated by the Company as a consequence thereof, and the ability of the Company to raise sufficient funding and to continue to develop its various business interests as presently contemplated. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.